Exclusive: Pfizer’s CEO on Q2 earnings
- blonca9
- Aug 1, 2023
- 1 min read
Albert Bourla discusses Q2 earnings, FTC and Seagen, Pfizer’s capacity for more deals, GLP-1s, and provides an update on the NC tornado damage.
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.